SANTA MONICA, Calif. – Mindfulness and meditation app provider Headspace has formed Headspace Health, a new, wholly owned subsidiary that will incorporate the Headspace meditation experience into digital medicine. The new company plans to deliver a prescription meditation app in 2020 when it anticipates the introduction of the first product in its portfolio of newly developed, clinically-validated and FDA-cleared meditation programs specifically designed to treat a broad range of chronic diseases. “The creation of Headspace Health is the most significant step ever taken to introduce meditation into medicine at scale,” said Rich Pierson, co-founder and CEO of Headspace, in a statement. “By standardizing meditation into health care, we’re bringing Headspace even closer to realizing our mission of improving health and happiness around the world.” Headspace Health is scheduled to begin randomized controlled trials this summer on its first targeted disease state, to be announced in the coming months. The completion of clinical trials and subsequent FDA submission are scheduled for 2020, with the goal of making Headspace Health’s initial prescription meditation program available to doctors. Headspace Health will be led by Dr. Joe Powers, as managing director.
You are here: / / Headspace creates subsidiary for prescription meditation app